Quantcast

Latest Dopamine agonists Stories

2010-10-06 07:45:00

NESS ZIONA, Israel, October 6, 2010 /PRNewswire/ -- NeuroDerm, Ltd. was informed today that it was awarded a grant of $1M by The Michael J. Fox Foundation for Parkinson's Research. These funds will support the next clinical study with ND0611, a new dermal patch for the treatment of Parkinson's disease, as part of the Foundation's prestigious Clinical Intervention Awards 2010 program. This study will evaluate the safety, tolerability, levodopa pharmacokinetics, and possible clinical...

2010-10-04 22:58:35

A researcher from the Faculty of Medicine & Dentistry at the University of Alberta has discovered a mechanism underlying some forms of obesity and addictions which could lead to a treatment for both diseases. When a hungry animal finds food in the wild, it is a rewarding stimulus for the animal and is recognized by the brain by the release of the chemical messenger dopamine. Because narcotics such as cocaine, heroin and amphetamines, and even tasty and highly-caloric foods also cause the...

2010-09-30 11:00:00

BRUSSELS, Sept. 30 /PRNewswire/ -- People with Parkinson's disease who used once-daily Neupro® (rotigotine) in the RECOVER trial achieved improvements in quality of life, in addition to previously reported beneficial effects on motor and non-motor symptoms. Data presented this week at the 2nd World Parkinson Congress in Glasgow, UK, showed that Neupro® provided clinically relevant improvements in PDQ-8 score. This is a self-administered health-related...

2010-09-28 06:58:00

NESS ZIONA, Israel, September 28, 2010 /PRNewswire/ -- NeuroDerm, Ltd. announce today that a platform presentation highlighting the company's new dermal patch for the treatment of Parkinson's disease, ND0611, was given yesterday at the 14th Congress of the European Federation of Neurological Societies in Geneva, Switzerland. A poster presentation will be given at the 2nd World Parkinson's Congress in Glasgow, Scotland. (Sep 28th - Oct 1st, 2010). The presentation described results of...

2010-09-09 07:00:00

BURLINGTON, Mass., Sept. 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, although increased uptake of currently-available therapies will drive modest $400 million growth in the Parkinson's disease drug market through 2019, generic erosion of key agents will constrain overall market growth in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. The Pharmacor 2010...

2010-08-16 09:12:00

HARRISBURG, Pa., Aug. 16 /PRNewswire-USNewswire/ -- On the street it's known as meth, speed, ice, chalk, crank, fire, glass or crystal. Methamphetamine is a highly addictive drug that wreaks havoc on the entire body, including the user's oral health. Approximately 10 million Americans have tried methamphetamine, while more than 1.4 million are habitual users. As the effects of methamphetamine use are devastating, the Pennsylvania Dental Association (PDA) wants to educate the public about...

2010-07-28 07:00:00

BRUSSELS, July 28 /PRNewswire/ -- UCB today announced the results of a 6-month, randomized, double-blind, placebo-controlled clinical study, published in the journal Movement Disorders, showing that Neupro® (rotigotine transdermal system, 2 and 3 mg/24 hours) provided sustained, clinically relevant improvements in symptoms of Restless Legs Syndrome (RLS). The study also showed high rates of complete remission seen with rotigotine 2 mg or 3 mg/24 hours. "In this study...

2010-07-26 15:15:00

SOUTH SAN FRANCISCO, Calif., July 26 /PRNewswire-FirstCall/ -- Titan Pharmaceuticals, Inc. (OTC Bulletin Board: TTNP) today announced that the National Institutes of Health (NIH) has awarded the company a grant under the Small Business Innovation Research (SBIR) program supporting the development of a long-term, non-fluctuating dopamine agonist treatment for Parkinson's disease. The first year award in the amount of $300,000 will be available to Titan starting August 1, 2010, and an...

2010-07-08 11:00:00

NEW YORK, July 8 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research today announced $1.1 million in total funding to six different projects aimed at validating potential therapeutic targets for Parkinson's disease. Target validation is an essential phase of drug development, yet a lack of funding for validation studies has long been a major roadblock to the efficient translation of promising discoveries into practical therapies for PD. The Foundation's...

2010-07-01 11:07:24

Brain study highlights role of dopamine in impulsive behavior It's a common scenario: you're on a diet, determined to give up eating cakes, but as you pass the cake counter, all resolve disappears"¦ Now, scientists at the Wellcome Trust Centre for Neuroimaging at UCL (University College London) have shed light on the brain processes that affect our will power and make us act impulsively. In a study published today in the Journal of Neuroscience, funded mainly by the Wellcome Trust,...


Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.